Last reviewed · How we verify

NCT07506395: GPAT

Group Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder

Not yet recruiting Phase 1 Last updated 1 April 2026
What this trial tests

Phase 1 trial testing Psilocybin in PTSD in 36 participants. Not yet recruiting.

Timeline
1 May 2026
Primary endpoint
1 May 2027
1 May 2028

Quick facts

Lead sponsorUniversity of New Mexico
PhasePhase 1
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment36
Start date1 May 2026
Primary completion1 May 2027
Estimated completion1 May 2028

Drugs / interventions tested

Conditions studied

Sponsor

University of New Mexico

Who can join

Adults 18 to 89, any sex, with PTSD. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a community-informed, pragmatic, open-label, phase 1 clinical trial of group-format psilocybin-assisted therapy (GPAT) for individuals with post-traumatic stress disorder (PTSD). The primary objectives of this phase 1 study are to assess the safety and feasibility of (GPAT) for individuals with (PTSD) and to evaluate preliminary effects on PTSD severity.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Psilocybin

Trials testing the same drug.

Other recruiting trials for PTSD

Currently open trials in the same condition.

Other University of New Mexico trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07506395.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing